This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Domperidone oral


Oral formulations of domperidone.

Drugs List

  • domperidone 10mg tablets
  • domperidone 1mg/ml oral suspension sugar-free
  • MOTILIUM 10mg tablets
  • Therapeutic Indications


    Nausea and vomiting

    Unlicensed Uses

    Gastro-intestinal pain in palliative care
    Gastro-oesophageal reflux disease


    Domperidone is recommended to be taken before meals.


    10mg up to three times a day.
    Maximum dose of 30mg daily.

    Gastro-intestinal pain in palliative care (unlicensed)
    10mg three times a day


    Children aged 12 to 18 years with bodyweight 35kg or above
    10mg up to three times a day.
    Maximum dose of 30mg daily.

    Gastro-oesophageal reflux disease (unlicensed)
    Children aged 1 month to 18 years
    250micrograms per kg three times a day. Maximum 10mg per dose.
    The dose may be increased to 400micrograms per kg three times a day if the response is inadequate. Maximum 20mg per dose.
    Treatment should be interrupted occasionally to assess recurrence, if the symptoms recur consider restarting treatment. Discontinue if the response is inadequate at a high dose.


    Gastro-oesophageal reflux disease (unlicensed)
    250micrograms per kg three times a day.
    The dose may be increased to 400micrograms per kg three times a day if the response is inadequate.
    Treatment should be interrupted occasionally to assess recurrence, if the symptoms recur consider restarting treatment. Discontinue if the response is inadequate at a high dose.

    Patients with Renal Impairment

    Severe renal impairment: When repeated doses, the frequency of administration, and possibly the dosage, needs to be reduced to once or twice daily depending on the degree of renal impairment. It is unlikely that a single dose in patients with impaired renal function needs adjustment.


    Cardiac disorder
    Gastrointestinal haemorrhage
    Gastrointestinal obstruction
    Gastrointestinal perforation
    Long QT syndrome
    Moderate hepatic impairment
    Torsade de pointes

    Precautions and Warnings

    Children under 12 years
    Family history of long QT syndrome
    Patients over 60 years
    Electrolyte imbalance
    Glucose-galactose malabsorption syndrome
    Hereditary fructose intolerance
    History of torsade de pointes
    Lactose intolerance
    Severe renal impairment

    Correct electrolyte disorders before treatment
    Reduce dose in patients with severe renal impairment
    Presentations with sorbitol unsuitable in hereditary fructose intolerance
    Some formulations contain hydroxybenzoate
    Some formulations contain lactose
    Perform ECG before and during treatment
    Monitor serum electrolytes
    Advise patient to report any signs of cardiac arrhythmias
    Predisposition QT prolongation: Counsel patient on symptoms of arrhythmias
    Discontinue treatment if arrhythmias occur
    Maintain treatment at the lowest effective dose
    Not licensed for all indications in all age groups
    Avoid use for more than 1 week
    Maintain treatment for the shortest possible duration
    Advise patient grapefruit products may increase plasma level

    Domperidone increases the risk of serious ventricular arrhythmias or sudden cardiac death, especially in patients older than 60 years, or patients taking a daily dose greater than 30mg.

    The risk of neurological side effects is higher in young children since metabolic functions and in the blood brain barrier are not fully developed in the first months of life.

    Pregnancy and Lactation


    Use domperidone with caution in pregnancy.

    There is limited data on the use of domperidone in pregnant women, the potential risk to humans is unknown.

    Studies in animals have shown reproductive toxicity at maternally toxic doses.

    The manufacturer recommends only using domperidone when it can be justified by the therapeutic benefit.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use domperidone with caution in breastfeeding.

    Domperidone is excreted in human breast milk and breastfed infants receive less than 0.1% of the maternal weight-adjusted dose. Occurrence of adverse effects, in particular cardiac effects cannot be excluded after exposure via breast milk. No adverse effects have been found in a limited number of published cases of breastfed infants whose mothers were taking domperidone.

    The manufacturers recommend making a decision whether to discontinue breastfeeding or to discontinue/abstain from domperidone therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. Caution should be exercised in case of QTc prolongation risk factors in breast-fed infants.

    Domperidone is sometimes used as a galactagogue to increase milk supply by increasing maternal serum prolactin. The clinical value in increasing milk supply in this way is questionable, and its benefit in women who continue to have insufficient milk production after nursing technique and frequency have been optimised has not been adequately studied. There is no officially established dosage for increasing milk supply.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Allergic reaction
    Altered liver function tests
    Anaphylactic reaction
    Anaphylactic shock
    Breast pain
    Breast tenderness
    Dry mouth
    Extrapyramidal effects
    Increased prolactin
    Oculogyric crisis
    Prolongation of QT interval
    Reduced libido
    Sudden cardiac death
    Torsades de pointes
    Urinary retention
    Ventricular arrhythmias


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2018

    Reference Sources

    Summary of Product Characteristics: Domperidone 1mg/ml Suspension. Wockhardt UK Ltd. Revised October 2019.
    Summary of Product Characteristics: Domperidone 10mg Film-coated Tablets. Wockhardt UK Ltd. Revised March 2018.
    Summary of Product Characteristics: Domperidone 1mg/ml oral suspension. Zentiva. Revised August 2018.
    Summary of Product Characteristics: Domperidone 10mg Tablets. Aurobindo Pharma Ltd. Revised November 2019.
    Summary of Product Characteristics: Motilium 10mg tablets. Zentiva. Revised September 2020.

    NICE Evidence Services Available at: Last accessed: 08 April 2021

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Domperidone. Last revised: 02 July 2018

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.